CONTEXT: An opinion piece on why more RWE is needed on how patients respond to biosimilars in oncology | “More evidence is the tool for persuading oncology providers to switch to biosimilars”
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 8
1. ““ Physicians are going to want data to understand that these truly are biosimilars that are interchangeable, and they’re not shortchanging their patients by doing this, even under pressure from payers. ””
2. “Physician Confidence in Biosimilars Rests on Real-world Data.”
3. “More evidence is the tool for persuading oncology providers to switch to biosimilars, said E. Randolph “Randy” Broun, MD, a blood and marrow transplant specialist with Oncology Hematology Care (OHC), in Cincinnati, Ohio.”
4. “Once we have so many Herceptins [trastuzumab], are they all the same?”
5. “But the FDA does not give it automatic interchangeable status, meaning pharmacists would be free to substitute the biosimilar with a reference product without informing the physician.”
Source URL: https://www.onclive.com/view/physician-confidence-in-biosimilars-rests-on-real-world-data